IgE receptor antagonists

Details IgE receptor antagonists IgE receptor antagonists

2006-09-05

2006-09-05

Russel, Jeffrey E. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C436S513000, C514S013800, C514S014800, C530S324000, C530S325000, C530S326000

Reexamination Certificate

active

07101851

ABSTRACT:
The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated FcεRI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides composition, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5627263 (1997-05-01), Ruoslahti et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5962634 (1999-10-01), Jameson et al.
patent: WO 89/02922 (1989-06-01), None
patent: WO 99/05271 (1999-04-01), None
Arap et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model”Science279:377-380 (1998).
Aruffo et al., “CD44 is the Principal Cell Surface Receptor for Hyaluronate”Cell61:1303-1313 (1990).
Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties”Proteins: Structure, Function, and Genetics8 (4) :309-314 (1990).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen”Journal of Molecular Biology293(4) :865-881 (1999).
Clackson and Wells, “In Vitro Selection from Protein and Peptide Libraries.”Trends Biotechnol. 12:173-184 (1994).
Creighton, Thomas E.Proteins: Structure and Molecular Properties, 2nd ed., W.H. Freeman and Company (1984) (table of contents only).
Cunningham et al., “Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor”EMBO Journal13(11):2508-2515 (1994).
Cwirla et al., “Peptide Agonist of the Thrombopoientin Receptor as Potent as the Natural Cytokine”Science276:1696-1699 (1997).
Cwirla et al., “Peptides on phage: a vast library of peptides for identifying ligands”Proc. Natl. Acad. Sci. USA87(16) :6378-6382 (1990).
Dennis et al., “Kunitz Domain Inhibitors of Tissue-Factor VIIa”Journal of Biological Chemistry269:22137-22144 (1994).
Dennis et al., “Peptide Exosite Inhibitors of Factor VIIa as Anticoagulants.”Nature404:465-470 (Mar. 2000).
Devlin et al., “Random peptide libraries: a source of specific protein binding molecules”Science249:404-406 (1990).
Garman et al., “Crystal Structure of the Human High-Affinity IgE Receptor”Cell95:951-961 (1998).
Garman et al., “Structure of the Fc fragment of human IgE bound to its high-affinity receptor FCERIα”Nature406:259-266 (2000).
Hakimi et al., “The α subunit of the human IgE receptor (FCERI) is sufficient for high affinity IgE binding”Journal of Biological Chemistry265(36) :22079-22081 (1990).
Ishizaka et al., “Biologic Function of the Fc Fragment of E Myeloma”Immunochemistry7:687-702 (1970).
Jardieu and Fick, “IgE Inhibition as a therapy for Allergic Disease”Intl. Arch. Allergy Immunol. 118:112-115 (1999).
Kinet J.P., “The High-Affinity IgE Receptor (FCERI) : From Physiology to Pathology”Ann. Rev. Immunol17:931-972 (1999).
Kolbinger et al., “A Humanized Antibody for the Treatment of Allergy”Protein Engineering(Abstract, top left), Oxford, GB 6(Suppl.):90 (1993).
Kunkel et al., “Efficient site-directed mutagenesis using uracil-containing DNA”Methods in Enzymology204:125-139 (1991).
Lowe et al., “Allergen-induced Histamine Release in Rat Mast Cells Transfected with the α Subunits of FCERI”J. Immunological Methods184:113-122 (1995).
Lowman and Wells, “Affinity Maturation of Human Growth Hormone by Monovalent Phage Display”J. Mol. Biol. 234:564-578 (1993).
Lowman and Wells, “Monovalent Phage Display: A Method for Selecting Variant Proteins from Random Libraries”Methods: Comp. to Methods Enzymol. 3:205-216 (1991).
Lowman et al., “Molecular Mimics of Insulin-Like Growth Factor 1 (IGF-1) for Inhibiting IGF-1: IGF-Binding Protein Interactions.”Biochemistry37 (25) :8870-8878 (1998).
Lowman et al., “Selecting High-Affinity Binding Proteins by Monovalent Phage Display”Biochemistry30 (45):10832-10838 (1991).
Lowman, H., “Bacteriophage display and discovery of peptide leads for drug development”Annual Review of Biophysics and Biomolecular Structure26:401-424 (1997).
Lowman, H., “Phage display of peptide libraries on protein scaffolds”Methods in Molecular Biology, Chapter 24, 87:249-264 (1998).
McDonnell et al., “Structure Based Design and Characterization of Peptides that Inhibit IgE Binding to Its High-affinity Receptor”Nature Structural Biology3 (5) :419-426 (May 1996).
McDonnell et al., “Structure-based design of peptides that inhibit IgE binding to its high-affinity receptor FCERI”Biochem Soc. Trans25:387-392 (1997).
Metzger et al., “The Receptor with High Affinity for Immunoglobulin E”Ann. Rev. Immunol4:419-470 (1986).
Nechansky et al., “The membrane-proximal part of FCERIα contributes to human IgE and antibody binding—implications for a general structural motif in Fc receptors”FEBS Letters441:225-230 (1998).
Nilsson et al., “Integrated production of human insulin and its C-peptide”Journal of Biotechnology48:241-250 (1996).
Nissim et al., “Mapping of the high affinity Fce receptor binding site to the third constant region domain of IgE”EMBO Journal10 (1) :101-107 (Jan. 1991).
Olivera et al., “Combinatorial peptide libraries in drug design: lessons from venomous cone snails”Trends BioTech13:422-426 (1995).
Pasqualini and Ruoslahti, “Organ Targeting In Vivo Using Phage Display Peptide Libraries.”Nature380:364-366 (1996).
Pelton et al., “Design and Synthesis of Conformationally Constrained Somatostatin Analogues with High Potency and Specificity for μ Opoid Receptors”J. Med. Chem. 29:2370-2375 (1986).
Presta et al., “Humanization of Antibody Directed Against IgE”J. Immunol. 151(5) :2623-2632 (Sep. 1, 1993).
Saini et al., “Down-Regulation of Human Basophil IgE and FCERIα Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible In Vitro and In Vivo”J. Immunol162:5624-5630 (1999).
Sawyer, T.K., “Peptidomimetic Design and Chemical Approaches to Peptide Metabolism”Peptide-Based Drug Design: Controlling Transport and Metabolism, Taylor and Amidon, Washington, DC:American Chemical Society pp. 387-422 (1995).
Sidhu et al., “Phage Display for Selection of Novel Binding Peptides”Methods Enzymology328:333-363 (2000).
Smith B.J., “Enzymatic Methods for Cleaving Proteins”Methods Mol. Biol. 32:289-296 (1994).
Stamenkovic et al., “The B Lymphocyte Adhesion Molecule CD22 Interacts with Leukocyte Common Antigen CD45RO on T Cells and α2-6 Sialyltransferase, CD75, on B Cells”Cell66:1133-1144 (1991).
Van Wezenbeek and Schoenmakers, “Nucleotide sequence of the genes III, VI, and I of bacteriophage M13”Nucleic Acids Research6:2799-2818 (1979).
Wells and Lowman, “Rapid Evolution of Peptide and Protein Binding Properties in Vitro”Curr. Opin. Struct. Biol. 2:597-604 (1992).
Wrighton et al., “Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin.”Science273:458-463 (1996).
Yanofsky et al., “High Affinity Type I Interleukin 1 Receptor Antagonists Discovered by Screening Recombinant Peptide Libraries.”Proc. Natl. Acad. Sci. USA93:7381-7386 (1996).
Takahashi et al., “Design of Peptides Derived from Anti-IgE Antibody for Allergic Treatment”B

Affiliated with

Also associated with

Rating

IgE receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IgE receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IgE receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3576768